Structure Therapeutics Inc. American Depositary Shares (GPCR : NASDAQ)
Common Stock
$35.50
USD
-3.45 (-8.86%)
Last updated: 2026-09-16
Get GPCR alerts:
GPCR
Structure Therapeutics Inc. American Depositary Shares
WealthAwesomePerformance
1 Day
-8.86%
1 Week
-13.90%
1 Month
-33.97%
YTD
-21.11%
Key Statistics
Market Cap
$2.53B
52W High
$94.90
52W Low
$22.70
P/E Ratio
-
50 Day MA
$49.13
200 Day MA
$54.51
Beta
-1.52
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/16/2026 | $39.19 | $39.19 | $35.42 | $35.50 | $35.50 | 1,204,635 |
| 9/15/2026 | $38.36 | $39.03 | $37.75 | $38.95 | $38.95 | 1,470,653 |
| 9/14/2026 | $38.92 | $39.24 | $37.82 | $38.44 | $38.44 | 1,498,347 |
| 9/11/2026 | $39.82 | $40.27 | $38.10 | $38.66 | $38.66 | 1,276,358 |
| 9/10/2026 | $40.51 | $40.90 | $39.29 | $39.55 | $39.55 | 761,400 |
| 9/9/2026 | $41.23 | $44.94 | $40.49 | $41.23 | $41.23 | 1,562,300 |
| 9/8/2026 | $46.84 | $47.38 | $40.26 | $40.38 | $40.38 | 3,409,900 |
| 9/4/2026 | $47.26 | $48.05 | $46.73 | $47.34 | $47.34 | 281,700 |
| 9/3/2026 | $48.21 | $48.25 | $46.37 | $47.34 | $47.34 | 621,400 |
| 9/2/2026 | $47.76 | $48.64 | $46.07 | $47.80 | $47.80 | 1,064,600 |
Analyst Price Targets
Based on 14 analysts covering GPCR · as of Sep 17, 2026
Wall Street analysts forecast GPCR stock price to rise 198.0% over the next 12 months.
Consensus
Strong Buy4.57 / 5.00
Avg. Target
US$105.78
+198.0% Upside
Current Price
US$35.50
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GPCR's historical volatility
30-Day Vol
64.2%
Annualized
90-Day Vol
58.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$29.69
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$33.45 | US$26.80 – US$41.74 |
| 60 trading days | US$31.52 | US$23.04 – US$43.11 |
| 90 trading days | US$29.69 | US$20.23 – US$43.58 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-265.79M
- Profit Margin
- 0.00%
- ROE (TTM)
- -20.21%
- EPS (Diluted)
- -2.75
- Book Value
- 19.02
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GPCR.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |